Foundry Healthcare Operating Profitability Factor ETF
ETF Foundry Research (hypothetical) · rebalanced monthly
Every other metric on this page is the long-shortstrategy, which needs a short book. This fund is the long leg alone, so these are the figures for what it actually holds. The bottom-bucket number is that basket’s own return — not short P&L.
Hypothetical growth of $1 — long-short backtest
Gross of the placeholder expense ratio and trading costs · not investor results
Holdings
Every constituent of the long leg — sort, search or filter by sector
| Ticker | Company | Sector | Market cap | Weight |
|---|---|---|---|---|
1LLY | ELI LILLY & CO | Healthcare | $1.11T | 30.86% |
2JNJ | JOHNSON & JOHNSON | Healthcare | $609.12B | 16.93% |
3MRK | MERCK & CO INC | Healthcare | $314.90B | 8.75% |
4AMGN | AMGEN INC | Healthcare | $197.69B | 5.49% |
5GILD | GILEAD SCIENCES INC | Healthcare | $166.72B | 4.63% |
6PFE | PFIZER INC | Healthcare | $142.77B | 3.97% |
7BMY | BRISTOL MYERS SQUIBB CO | Healthcare | $124.04B | 3.45% |
8VRTX | VERTEX PHARMACEUTICALS INC | Healthcare | $123.26B | 3.43% |
9REGN | REGENERON PHARMACEUTICALS INC | Healthcare | $70.94B | 1.97% |
10COR | CENCORA INC | Healthcare | $59.91B | 1.67% |
11IDXX | IDEXX LABORATORIES INC | Healthcare | $44.76B | 1.24% |
12TEVA | TEVA PHARMACEUTICAL INDUSTRIES LTD | Healthcare | $37.30B | 1.04% |
13ALNY | ALNYLAM PHARMACEUTICALS INC | Healthcare | $35.71B | 0.99% |
14ONC | BEONE MEDICINES LTD | Healthcare | $34.68B | 0.96% |
15IQV | IQVIA HOLDINGS INC | Healthcare | $34.42B | 0.96% |
16ZTS | ZOETIS INC | Healthcare | $32.10B | 0.89% |
17DXCM | DEXCOM INC | Healthcare | $29.58B | 0.82% |
18RMD | RESMED INC | Healthcare | $28.86B | 0.80% |
19GEHC | GE HEALTHCARE TECHNOLOGIES INC | Healthcare | $28.69B | 0.80% |
20ILMN | ILLUMINA INC | Healthcare | $28.24B | 0.78% |
21INCY | INCYTE CORP | Healthcare | $23.42B | 0.65% |
22UTHR | UNITED THERAPEUTICS CORP | Healthcare | $22.74B | 0.63% |
23NBIX | NEUROCRINE BIOSCIENCES INC | Healthcare | $17.18B | 0.48% |
24THC | TENET HEALTHCARE CORP | Healthcare | $16.79B | 0.47% |
25JAZZ | JAZZ PHARMACEUTICALS PLC | Healthcare | $15.53B | 0.43% |
26MEDP | MEDPACE HOLDINGS INC | Healthcare | $15.36B | 0.43% |
27EXEL | EXELIXIS INC | Healthcare | $14.06B | 0.39% |
28PODD | INSULET CORP | Healthcare | $11.36B | 0.32% |
29EHC | ENCOMPASS HEALTH CORP | Healthcare | $11.13B | 0.31% |
30ARWR | ARROWHEAD PHARMACEUTICALS INC | Healthcare | $10.47B | 0.29% |
31CORT | CORCEPT THERAPEUTICS INC | Healthcare | $9.72B | 0.27% |
32HALO | HALOZYME THERAPEUTICS INC | Healthcare | $9.23B | 0.26% |
33UHS | UNIVERSAL HEALTH SERVICES INC | Healthcare | $9.15B | 0.25% |
34IONS | IONIS PHARMACEUTICALS INC | Healthcare | $8.99B | 0.25% |
35ALKS | ALKERMES PLC | Healthcare | $8.79B | 0.24% |
36TGTX | TG THERAPEUTICS INC | Healthcare | $8.40B | 0.23% |
37HQY | HEALTHEQUITY INC | Healthcare | $8.17B | 0.23% |
38PACS | PACS GROUP INC | Healthcare | $7.30B | 0.20% |
39MIRM | MIRUM PHARMACEUTICALS INC | Healthcare | $7.25B | 0.20% |
40LQDA | LIQUIDIA CORP | Healthcare | $7.11B | 0.20% |
41LNTH | LANTHEUS HOLDINGS INC | Healthcare | $7.00B | 0.19% |
42CHE | CHEMED CORP | Healthcare | $6.77B | 0.19% |
43TVTX | TRAVERE THERAPEUTICS INC | Healthcare | $5.27B | 0.15% |
44SHC | SOTERA HEALTH CO | Healthcare | $5.06B | 0.14% |
45KNSA | KINIKSA PHARMACEUTICALS INTERNATIONAL PLC | Healthcare | $4.92B | 0.14% |
46LIVN | LIVANOVA PLC | Healthcare | $4.43B | 0.12% |
47ACAD | ACADIA PHARMACEUTICALS INC | Healthcare | $4.38B | 0.12% |
48CON | CONCENTRA GROUP HOLDINGS PARENT INC | Healthcare | $4.04B | 0.11% |
49DOCS | DOXIMITY INC | Healthcare | $3.94B | 0.11% |
50CPRX | CATALYST PHARMACEUTICALS INC | Healthcare | $3.85B | 0.11% |
51NHC | NATIONAL HEALTHCARE CORP | Healthcare | $3.56B | 0.10% |
52ARQT | ARCUTIS BIOTHERAPEUTICS INC | Healthcare | $3.56B | 0.10% |
53OGN | ORGANON & CO | Healthcare | $3.55B | 0.10% |
54HAE | HAEMONETICS CORP | Healthcare | $3.54B | 0.10% |
55GRDN | GUARDIAN PHARMACY SERVICES INC | Healthcare | $2.57B | 0.07% |
56TMDX | TRANSMEDICS GROUP INC | Healthcare | $2.56B | 0.07% |
57AVAH | AVEANNA HEALTHCARE HOLDINGS INC | Healthcare | $2.11B | 0.06% |
58ADMA | ADMA BIOLOGICS INC | Healthcare | $2.02B | 0.06% |
59HRMY | HARMONY BIOSCIENCES HOLDINGS INC | Healthcare | $1.96B | 0.05% |
60SRPT | SAREPTA THERAPEUTICS INC | Healthcare | $1.82B | 0.05% |
61ANIP | ANI PHARMACEUTICALS INC | Healthcare | $1.80B | 0.05% |
62IMCR | IMMUNOCORE HOLDINGS PLC | Healthcare | $1.78B | 0.05% |
63HROW | HARROW INC | Healthcare | $1.74B | 0.05% |
64TDOC | TELADOC HEALTH INC | Healthcare | $1.70B | 0.05% |
65ANAB | ANAPTYSBIO INC | Healthcare | $1.69B | 0.05% |
66XERS | XERIS BIOPHARMA HOLDINGS INC | Healthcare | $1.52B | 0.04% |
67ARDT | ARDENT HEALTH INC | Healthcare | $1.46B | 0.04% |
68AMN | AMN HEALTHCARE SERVICES INC | Healthcare | $1.36B | 0.04% |
69PAHC | PHIBRO ANIMAL HEALTH CORP | Healthcare | $1.35B | 0.04% |
70IRMD | IRADIMED CORP | Healthcare | $1.24B | 0.03% |
71TNDM | TANDEM DIABETES CARE INC | Healthcare | $1.17B | 0.03% |
72COLL | COLLEGIUM PHARMACEUTICAL INC | Healthcare | $1.17B | 0.03% |
73NUTX | NUTEX HEALTH INC | Healthcare | $1.12B | 0.03% |
74HSTM | HEALTHSTREAM INC | Healthcare | $832M | 0.02% |
75RIGL | RIGEL PHARMACEUTICALS INC | Healthcare | $750M | 0.02% |
76PHR | PHREESIA INC | Healthcare | $662M | 0.02% |
77CRMD | CORMEDIX INC | Healthcare | $661M | 0.02% |
78NRC | NRC HEALTH | Healthcare | $491M | 0.01% |
79PBYI | PUMA BIOTECHNOLOGY INC | Healthcare | $434M | 0.01% |
80TBRG | TRUBRIDGE INC | Healthcare | $394M | 0.01% |
81QTTB | Q32 BIO INC | Healthcare | $255M | 0.01% |
82SMTI | SANARA MEDTECH INC | Healthcare | $229M | 0.01% |
83SPOK | SPOK HOLDINGS INC | Healthcare | $222M | 0.01% |
84PDEX | PRO DEX INC | Healthcare | $183M | 0.01% |
85CUE | CUE BIOPHARMA INC | Healthcare | $126M | 0.00% |
86CSBR | CHAMPIONS ONCOLOGY INC | Healthcare | $85M | 0.00% |
87SNWV | SANUWAVE HEALTH INC | Healthcare | $55M | 0.00% |
88XLO | XILIO THERAPEUTICS INC | Healthcare | $53M | 0.00% |
Full long-leg book as of July 2026 · cap-weighted · total market cap $3.60T. Hypothetical model holdings — not a registered fund’s portfolio.
Sector Breakdown
Portfolio Style
Size × value map of the long-leg book
Share of long-leg capital by market cap × book-to-market, using terciles of the 499-name universe at July 2026. Rows: Large ≥ $3.6B, Small < $964M. Columns: Value ≥ 0.67, Growth < 0.37 B/M. The dot marks the capital-weighted centroid of the book — 99% toward Large, 61% toward Growth. Hypothetical holdings — descriptive, not realized P&L.
Capital-weighted centroid of the long leg, December 1998 → July 2026; the right-hand end is the same value as the box’s dot. 88 names now. Hypothetical holdings — descriptive, not P&L.
Constraint checks
How this book measures against the concentration and liquidity rules — as implemented here
These are UNCONSTRAINED factor sleeves: the construction pipeline sorts on a signal and cap-weights the top bucket, applying no issuer cap, no industry cap and no liquidity screen beyond the universe filter. A failing test therefore reports a constraint that was never applied during construction — it is not a defect in the strategy and not an error in the data. The same signal can be solved subject to these constraints.
7 independent checks plus 1 arithmetically implied by another check (RIC / IRC 851(b)(3)(A) 50% bucket), which is reported separately so the tally cannot overstate scrutiny.
1 of 7 checks could not be tested. Those are neither passes nor failures — they are gaps in what the data can answer, and they are excluded from the passed count above rather than folded into it.
With respect to 75% of total assets, no more than 5% may be invested in the securities of any one issuer.
Required>= 75.0%Actual58.0%Margin-17.0%No more than 25% of total assets may be invested in the securities of any one issuer.
Required<= 25.0%Actual30.9%Margin-5.9%Days required to liquidate the largest position at 20% of one day's dollar volume.
Required<= 7.0 daysActualunboundedMargin—
Engineering approximation of the cited rules for a DRAFT / HYPOTHETICAL model portfolio that is not a registered fund. This reports whether the portfolio passes the stated test AS IMPLEMENTED HERE; it is not a compliance opinion and is not a statement that any fund is compliant. Real filings need securities counsel.
No verdict sits within 1.0pp of its limit.
Data version — panel=20260719T025334 rows=2239262 asof=202607 issuers=20260719T014536 rates=20260804T224700
Measured on the 2026-07 formation date across 88 holdings (cap-weighted). A different formation date can produce different verdicts.
Derivatives risk (Rule 18f-4)
Whether this long-only book is subject to the VaR tests at all
This assessment describes the long-only book this fund holds — the top bucket only.
This fund QUALIFIES for the limited-derivatives-user exception, so it is excepted from the VaR tests; the ratio below is informational, not the operative limit.
Rule 18f-4(c)(4): a fund whose derivatives exposure (gross notional, including the value of assets sold short) is <= 10% of net assets is excepted from the VaR tests and the full derivatives risk management program.
No confidence interval: this follows from portfolio construction, not from an estimate.
Rule 18f-4(c)(2)(i): fund VaR at 99% over 20 trading days must not exceed 200% of the designated reference portfolio's VaR on the same basis.
Informational — does not governThis fund is excepted from the VaR tests, so the ratio below is context rather than the operative limit. It is shown because it is still a description of the book’s risk, not because it decides anything.
historical method · 331 monthly observations · about 3.3 in the 99% tail · paired percentile bootstrap over months
The estimators agree, which is mild evidence the number isn’t an artefact of one method.
Engineering approximation of SEC Rule 18f-4 for research display. Not a compliance opinion and not a determination that any fund is compliant. Hypothetical model portfolio, not a registered fund.
The research long-short construction behind this factor does not qualify for this exception — a dollar-neutral book counts its full short notional, which is 100% of net assets against a 10% threshold. This product sidesteps that by holding the long leg alone, which is also why the long-leg Sharpe is reported separately throughout the site.
See the long-short verdict on the factor page →Since publication
Did the edge survive the paper coming out?
Split at January of the year after the factor was published. The post-publication stretch IS genuinely out-of-sample relative to the original study -- the predictor was public by then -- so it speaks to whether the effect survived being known. Nothing is fitted here, so this is performance SINCE PUBLICATION, not validation of a model. Note the 'pre' side is our data before publication (our panel starts ~1999), NOT the study's original in-sample period, which usually ran decades earlier; a decay figure compares before-vs-after within our sample and is not a comparison against the published result.
Consistency across eras
Is this record broadly durable, or one regime?
3-year rolling windows, stepping 1 year (26 windows). Dispersion is the spread of window Sharpes — higher means the record depends more on which era you look at.
Rules-based factors fit no parameters, so these windows are not out-of-sample tests and do not validate a fitted model. They show whether the factor's record is consistent across eras or driven by one regime.
Returns
Long leg is what this fund holds — long-short is shown for reference
| Period | Long leg | Long-short |
|---|---|---|
| 1 yearcum. | 38.6% | -3.9% |
| 3 yearsp.a. | 12.4% | -13.3% |
| 5 yearsp.a. | 8.8% | 0.6% |
| 10 yearsp.a. | 11.2% | 1.0% |
| Since inceptionp.a. | 9.2% | -1.5% |
| Year | Long leg | Long-short |
|---|---|---|
| 20267 mo | 9.6% | 5.5% |
| 2025 | 20.4% | -25.0% |
| 2024 | 3.7% | -5.4% |
| 2023 | 3.0% | -20.1% |
| 2022 | 0.8% | 34.3% |
| 2021 | 26.9% | 66.4% |
| 2020 | 14.1% | -24.9% |
| 2019 | 19.9% | -4.5% |
| 2018 | 6.2% | 35.5% |
| 2017 | 20.9% | -13.3% |
| 2016 | -4.3% | 5.4% |
| 2015 | 3.7% | 3.4% |
| 2014 | 25.5% | -22.2% |
| 2013 | 51.2% | 7.1% |
| 2012 | 24.6% | 10.6% |
| 2011 | 12.8% | 21.1% |
| 2010 | 3.5% | 1.6% |
| 2009 | 21.7% | -7.8% |
| 2008 | -17.0% | 46.8% |
| 2007 | 4.4% | 6.5% |
| 2006 | 8.0% | 5.1% |
| 2005 | 5.4% | 12.5% |
| 2004 | 7.1% | 3.1% |
| 2003 | 9.0% | -34.7% |
| 2002 | -19.7% | 66.2% |
| 2001 | -13.2% | -16.0% |
| 2000 | 40.7% | -51.5% |
| 1999 | -4.7% | -38.7% |
Long leg = the top bucket this fund holds; long-short additionally shorts the bottom bucket and is not achievable in a long-only vehicle. Trailing figures run through July 2026: 1 year is a plain cumulative 12-month return (cum.), 3 years and longer are annualised (p.a.). Years marked with a month count are partial. These match the fact sheet’s tables by construction. Hypothetical backtest, gross of the placeholder expense ratio and trading costs — not investor results.
Fund Facts
Methodology
The Foundry Healthcare Operating Profitability Factor ETF tracks a rules-based model that ranks Healthcare common stocks each month by a Operating Profitability signal and holds the top quintile with the highest values. Signals are computed from point-in-time Sharadar fundamentals and total-return prices. The portfolio reconstitutes monthly and is cap-weighted within the long leg.
This is a hypothetical model portfolio for research display only — not a registered fund, not an offer, and not investment advice.
Documents (draft — hypothetical)
Auto-generated from the model’s metrics and current holdings. Every document is labeled DRAFT / hypothetical.
Objective, fees, strategy, and key risks.
Full strategy, model methodology, and risks.
Policies, construction, and governance.
One-page snapshot with top holdings.
Full current constituent list.
DRAFT — HYPOTHETICAL MODEL PORTFOLIO — NOT A REGISTERED FUND, NOT AN OFFER TO SELL SECURITIES, NOT INVESTMENT ADVICE.